L
Lusaris Therapeutics
A biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders
About Lusaris Therapeutics
Lusaris Therapeutics, Inc. is a biotechnology company established in 2021 with a focus on developing treatments for severe neuropsychiatric and neurological disorders. The company launched in November 2022 with a significant $60 million Series A financing round led by its incubator, RA Capital Management, with participation from other healthcare investors including Venrock Healthcare Capital Partners, Deep Track Capital, and Boxer Capital. The founding team consists of experienced drug developers and company builders with a strong background in neuroscience. The leadership team included Andrew Levin, M.D., Ph.D., as interim CEO, and Neil Buckley, M.S., as Chief Operating Officer.
The company's primary business is the advancement of next-generation serotonergic neuroplastogen therapeutics. Its business model revolves around the clinical development and eventual commercialization of these novel drugs. The target market includes patients suffering from severe conditions that are not adequately addressed by current treatments. Lusaris' lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a potent and fast-acting psychedelic compound. This compound is being developed for patients with Treatment-Resistant Depression (TRD) and other acute mental health disorders. The treatment aims to induce favorable structural and functional neural plasticity, offering rapid improvements for patients. LSR-1019 is designed as a fast-dissolving tablet that is placed under the tongue, allowing for rapid absorption into the bloodstream. This delivery method, using Catalent's Zydis technology through an exclusive worldwide license, is intended to be scalable and simplify administration for both patients and physicians. Beyond TRD, Lusaris' pipeline also included the development of novel neuroplastogens for other conditions such as migraine and cluster headaches.
Despite a promising start, the company's operational status has become unclear. By September 2023, reports indicated that the company's website was no longer active, and key personnel, including the COO, had moved to other roles. PitchBook data from May 2023 lists the company as "Out of Business". There has been no official news or press releases from the company since its initial financing announcement in late 2022, leading to speculation about its current activities.
Source: Dealroom company dataNews
Open roles
Lusaris Therapeutics in the Boston ecosystem
The Lusaris Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Boxer Capital
RA Capital Management
Deep Track Capital- VPVenrock Healthcare Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lusaris Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lusaris Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

